Endothelial cell in venous malformation

Endothelial cells in venous malformation are not a single molecular entity but represent the abnormal endothelial cell population lining dysplastic veins within venous malformations, a type of vascular anomaly. These cells may harbor somatic mutations, most notably in genes like TIE2 (TEK) and PIK3CA, leading to pathological signaling that causes vascular dilation, abnormal vessel wall structure, and ultimately clinical symptoms. They are not a discrete receptor, enzyme, or classic molecular drug target; instead, their abnormal behavior results from upstream genetic alterations and dysregulated pathways such as PI3K/AKT and VEGF signaling. Although not a canonical therapeutic target themselves, drugs such as sirolimus (rapamycin), which act on the mTOR pathway, have been repurposed to mitigate the pathological proliferation and abnormal angiogenesis driven by these cells in venous malformations. Key clarifications: "Endothelial cells in venous malformation" refers to a cell population, not a canonical molecular target such as a receptor or enzyme. The more specific and actionable molecular targets in venous malformations are TIE2 (TEK) and PIK3CA. Therefore, the designation "is_incorrect: true" applies because a cell population is not a standard molecular therapeutic target and would not be directly actionable in structured drug-target databases.

Other names

Endothelial cells in venous malformationsVenous malformation endothelial cell

mTOR inhibition (Sirolimus/rapamycin reduces endothelial cell proliferation and migration in lesions)